TNFSF10 and neoplasm: However, Buchsbaum et al. demonstrated that the combination of a TRAIL death receptor agonist and radiation or TRAIL agonist, doxorubicin, and radiation showed increased tumor growth inhibition compared to single agents in an in vivo xenograft model using a derivative of the MDA-MB-231 cell line which is p53 mutant [89].